Department of Radiomedical Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Nuclear Science and Technology Research Institute (NSTRI), Iran.
Appl Radiat Isot. 2022 Aug;186:110273. doi: 10.1016/j.apradiso.2022.110273. Epub 2022 May 11.
The goal of using radiopharmaceuticals for therapeutic purposes is twofold: first, the most damage to cancer cells and, second, the most negligible dose transfers to healthy tissues. As Lu has the potential to cure a wide range of malignancies due to its varied range of beta energies, Lu-BBN-GABA-DOTA has been developed for therapeutic applications. In addition, Lu-BBN-GABA-DOTA can be over-expressed on gastrin-releasing peptide (GRP) receptors of the prostate, breast, small cell lung cancer, gastric, and colon tumors. The purpose of this study was to calculate the amount of dose absorption in human body organs using medical internal radiation dose (MIRD) and GATE code methods, after animal injection. In this study, the amount of absorbed dose in different organs (spleen, kidney, Lung, Pancreas, Heart, Adrenal, Intestine, Stomach, and Liver) were calculated for 1-MBq accumulation of Lu-BBN-GABA-DOTA in source organs (spleen, kidney, Lung, Pancreas, Heart, Adrenal, Intestine, Stomach, and Liver) using Monte Carlo Simulation (GATE code) with Zubal phantom. Moreover, compared with MIRD method, the results of the simulation showed considerable consistency. It was estimated that a 1-MBq administration of Lu-BBN-GABA-DOTA to the human body would result in an absorbed dose of 1.07E-02 mGy and 4.97E-02 (MIRD method) and 1.26E-02 mGy and 5.19E-02 (Gate code) in the Pancreas and adrenal 120 h after injection, respectively. The highest and lowest percentage differences between MIRD and Gate results are related to the Pancreas and spleen, respectively. Finally, the results showed that there is a good agreement between MIRD method and Gate code simulation for absorbed dose estimation.
第一，对癌细胞的损伤最大，第二，对健康组织的剂量转移最小。由于镥具有多种β能量，因此有可能治愈广泛的恶性肿瘤，因此已经开发了 Lu-BBN-GABA-DOTA 用于治疗应用。此外，Lu-BBN-GABA-DOTA 可以在胃泌素释放肽 (GRP) 受体过度表达于前列腺、乳腺、小细胞肺癌、胃和结肠肿瘤。本研究的目的是使用医学内部辐射剂量 (MIRD) 和 GATE 代码方法计算动物注射后人体器官吸收剂量的量。在这项研究中，计算了不同器官（脾脏、肾脏、肺、胰腺、心脏、肾上腺、肠、胃和肝脏）吸收剂量的量，对于在脾脏、肾脏、肺、胰腺、心脏、肾上腺、肠、胃和肝脏等源器官中积累的 1-MBq Lu-BBN-GABA-DOTA，使用蒙特卡罗模拟 (GATE 代码) 和 Zubal 体模进行了计算。此外，与 MIRD 方法相比，模拟结果显示出相当大的一致性。据估计，将 1-MBq Lu-BBN-GABA-DOTA 施用于人体将导致 1.07E-02 mGy 和 4.97E-02（MIRD 方法）和 1.26E-02 mGy 和 5.19E-02（Gate 代码）在注射后 120 小时分别在胰腺和肾上腺中吸收剂量。MIRD 和 Gate 结果之间的最高和最低百分比差异分别与胰腺和脾脏有关。最后，结果表明，MIRD 方法和 Gate 代码模拟在吸收剂量估计方面具有良好的一致性。
